Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure

Table 2

Serum biochemistry, after 4 weeks of binder treatment, at time of sacrifice.

		Weight; g	Creatinine; μmol/L	Ca; mmol/L	P; mmol/L	iPTH; pg/mL	AP; mmol/L	Ht; %	Ferritin; ng/mL	FGF23; ng/mL
CRF control	18	313 ± 5	144 ± 11	2.32 ± 0.05	3.30 ± 0.29	3567 ± 593	430 ± 26	26.7 ± 0.5	2359 ± 281	0.7 (0.1–9.7)
CRF PA21	19	302 ± 4	141 ± 10	2.45 ± 0.03	2.06 ± 0.06^a	1459 ± 242^a	363 ± 19	26.4 ± 0.5	2185 ± 173	0.2 (0.1–7.6)^a
CRF Se	20	298 ± 4	147 ± 11	2.48 ± 0.03^a	2.51 ± 0.12^a	1569 ± 238^a	367 ± 19	21.9 ± 0.5^a	2188 ± 134	0.4 (0.1–10.6)
CRF La	18	309 ± 4	140 ± 7.9	2.52 ± 0.03^a	2.24 ± 0.07^a	1360 ± 170^a	379 ± 29	22.7 ± 0.5^a	2361 ± 184	0.3 (0.1–9.1)

Ca, calcium; Ht, hematocrit; iPTH, intact parathyroid hormone; La, lanthanum carbonate; AP, alkaline phosphatase; P, phosphorus; Se, sevelamer carbonate; PA21, sucroferric oxyhydroxide. ^a versus CRF control. Values shown are mean ± SE except for FGF23 (median and range).